Catalyst Capital Advisors LLC trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,654 shares of the biopharmaceutical company’s stock after selling 8,055 shares during the quarter. Catalyst Capital Advisors LLC’s holdings in Gilead Sciences were worth $3,942,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. Welch Investments LLC acquired a new position in Gilead Sciences during the 3rd quarter worth approximately $108,000. Hanson & Doremus Investment Management increased its position in Gilead Sciences by 806.5% during the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 1,613 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Gilead Sciences during the 2nd quarter worth approximately $147,000. Harel Insurance Investments & Financial Services Ltd. increased its position in Gilead Sciences by 29.3% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 480 shares in the last quarter. Finally, Rowland & Co. Investment Counsel ADV acquired a new position in Gilead Sciences during the 2nd quarter worth approximately $153,000. Institutional investors and hedge funds own 75.95% of the company’s stock.
GILD has been the subject of a number of research analyst reports. Berenberg Bank set a $96.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Credit Suisse Group restated a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a research report on Thursday, December 7th. Zacks Investment Research cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, December 27th. Finally, Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price target for the company in a research report on Friday, October 13th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eighteen have assigned a buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and an average price target of $85.53.
In related news, insider John F. Milligan sold 220,000 shares of the stock in a transaction on Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP James R. Meyers sold 100,000 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the transaction, the executive vice president now directly owns 102,715 shares in the company, valued at $8,241,851.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 591,666 shares of company stock worth $44,466,567. Insiders own 1.30% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $80.98 on Friday. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The company has a market cap of $105,510.00, a price-to-earnings ratio of 9.21, a PEG ratio of -1.77 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same period in the prior year, the firm posted $2.75 EPS. The company’s quarterly revenue was down 13.2% on a year-over-year basis. sell-side analysts anticipate that Gilead Sciences, Inc. will post 8.48 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.66%.
COPYRIGHT VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/20/gilead-sciences-inc-gild-shares-sold-by-catalyst-capital-advisors-llc.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.